Sustained effects of nonallele‐specific Huntingtin silencing
- 18 March 2009
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 65 (3), 276-285
- https://doi.org/10.1002/ana.21569
Abstract
Objective Huntington's disease (HD) is a fatal autosomal dominant neurodegenerative disorder caused by a polyglutamine expansion in the huntingtin (htt) protein. No cure is available to date to alleviate neurodegeneration. Recent studies have demonstrated that RNA interference represents a promising approach for the treatment of autosomal dominant disorders. But whether an allele‐specific silencing of mutant htt or a nonallele‐specific silencing should be considered has not been addressed. Methods We developed small hairpin RNA targeting mutant or wild‐type htt transcripts, or both. Results We confirmed the therapeutic potential of sihtt administered with lentiviral vectors in rodent models of HD and showed that initiation of small interfering RNA treatment after the onset of HD symptoms is still efficacious and reduces the HD‐like pathology. We then addressed the question of the impact of nonallele‐specific silencing and demonstrated that silencing of endogenous htt to 25 to 35% in vivo is altering several pathways associated with known htt functions but is not inducing overt toxicity or increasing striatal vulnerability up to 9 months after treatment. Interpretation These data indicate that the coincident silencing of the wild‐type and mutant htt may be considered as a therapeutic tool for HD. Ann Neurol 2009;65:276–285Keywords
This publication has 35 references indexed in Scilit:
- Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAiProceedings of the National Academy of Sciences of the United States of America, 2008
- Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficitsProceedings of the National Academy of Sciences of the United States of America, 2007
- High-Capacity Adenoviral Vector-Mediated Reduction of Huntingtin Aggregate Load In Vitro and In VivoHuman Gene Therapy, 2007
- rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouseBiochemical and Biophysical Research Communications, 2006
- siRNA-mediated inhibition of endogenous Huntington disease gene expression induces an aberrant configuration of the ER network in vitroBiochemical and Biophysical Research Communications, 2005
- Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic miceMolecular Therapy, 2005
- Adenovirus-Mediated Silencing of Huntingtin Expression by shRNAHuman Gene Therapy, 2005
- Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interferenceBiochemical and Biophysical Research Communications, 2005
- RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxiaNature Medicine, 2004
- Induction of an interferon response by RNAi vectors in mammalian cellsNature Genetics, 2003